SCHEMBL6678978

SCHEMBL6678978

CCNC(=O)Nc1ccc(Cn2c(=O)[nH]c3c(c2=O)C=C(C(=O)O)CO3)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.35
POLB P06746 4/20 0.35
RAB9A P51151 2/20 0.35
TP53 P04637 2/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 8/20 0.35
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
HDAC6 Q9UBN7 1/20 0.34
MAPK1 P28482 1/20 0.34
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 2/20 0.33
PIK3CA P42336 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MTOR P42345 1/20 0.33
PIK3CG P48736 1/20 0.33
ESR1 P03372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6685031 0.83 HPGD (0.43) POLBTP53MAPTHPGDHSD17B10
SCHEMBL6677757 0.82 ABCB1 (0.37) ABCB1POLBRAB9ATP53NPC1
SCHEMBL7061233 0.81 ABCB1 (0.35) ABCB1POLBRAB9ATP53NPC1
SCHEMBL6685457 0.81 ABCB1 (0.35) ABCB1POLBRAB9ATP53NPC1
SCHEMBL6678246 0.77 ALDH1A1 (0.36) ALDH1A1KMT2A
SCHEMBL7062180 0.72 MTHFD2 (0.39) ABCB1POLBRAB9ATP53NPC1
SCHEMBL6789699 0.70 MAPT (0.49) RAB9ATP53MAPTHPGDLMNA
SCHEMBL6681686 0.67 MMP1 (0.46) TP53MAPTHSD17B10LMNASMN1; SMN2
SCHEMBL6682049 0.67 ABCB1 (0.35) ABCB1POLBRAB9ATP53NPC1
SCHEMBL6678347 0.64 ALDH1A1 (0.43) RAB9AHPGDHSD17B10LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 ABCB1 624/4885POLB 127/4885RAB9A 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.